# EB-NK-301

Source: https://onco.cc/drugs/eb-nk-301/  
OnCo record `eb-nk-301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EB-NK-301 is an experimental donor-derived immune-cell therapy aimed at TROP2. Its registered trial combines phase 1 and phase 2 testing; no clinical benefit is established.

## Summary

EB-NK-301 is an allogeneic TROP2 CAR-NK product in NCT07589530, a recruiting phase 1/2 study. The registry plans 60 participants and marks the March 2, 2026 start as actual. Primary completion is estimated for February 14, 2027; the record was last updated May 15, 2026. No tabular results are posted. The combined phase 1/2 designation does not establish completed phase 2 efficacy or postoperative TNBC benefit.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Also known as: TROP2-CAR NK
- Tags: pipeline; ctgov-ingest
- Modality: CAR-NK cell therapy
- Mechanism: CAR-NK cell therapy directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov NCT07589530: https://clinicaltrials.gov/study/NCT07589530

## Connected records

- technologies: [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors](https://onco.cc/trials/nct07589530/)

---
JSON: https://onco.cc/api/v1/entities/eb-nk-301.json